Opendata, web and dolomites

Medicortex

Launching the First Non-Invasive Point of Care Diagnostic Test for Traumatic Brain Injury

Total Cost €

0

EC-Contrib. €

0

Partnership

0

Views

0

 Medicortex project word cloud

Explore the words cloud of the Medicortex project. It provides you a very rough idea of what is the project "Medicortex" about.

biomarkers    lasse    proven    moderate    single    charged    billion    25    kvist    industry    25x    margin    saliva    charge    diagnostics    innovation    bioanalytical    risks    injuries    rten    pharmaceutical    care    mri    instead    biomarker    dr    head    tbi    patents    always    unfortunately       providers    healthcare    ct    ed    accurate    confirmed    suggested    dizziness    annually    director    medicortex    innovative    envision    sell    500    protected    price    patient    depression    efficient    tools    biotech    sufficient    auml    quick    untreated    headache    point    urine    nervous    aring    traumatic    limaa    brain    diagnose    50    diagnostic    evaluations    correlated    distributors    scan    none    poc    approved    standard    medical    active    anxiety    reduce    spinal    identification    impairment    injury    putting    glycan    scans    correctly    cognitive    letter    accurately    central    difficult    irritability    academia    samples    track    cord    market    founder    record    exceed    90    harel    kit    tests    mild   

Project "Medicortex" data sheet

The following table provides information about the project.

Coordinator
MEDICORTEX FINLAND OY 

Organization address
address: ITAINEN PITKAKATU 4B 4
city: TURKU
postcode: 20520
website: n.a.

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.

 Coordinator Country Finland [FI]
 Project website http://www.medicortex.fi
 Total cost 71˙429 €
 EC max contribution 50˙000 € (70%)
 Programme 1. H2020-EU.3. (PRIORITY 'Societal challenges)
2. H2020-EU.2.3. (INDUSTRIAL LEADERSHIP - Innovation In SMEs)
3. H2020-EU.2.1. (INDUSTRIAL LEADERSHIP - Leadership in enabling and industrial technologies)
 Code Call H2020-SMEInst-2018-2020-1
 Funding Scheme SME-1
 Starting year 2018
 Duration (year-month-day) from 2018-11-01   to  2019-02-28

 Partnership

Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    MEDICORTEX FINLAND OY FI (TURKU) coordinator 50˙000.00

Map

 Project objective

Traumatic Brain Injury (TBI) is the leading cause of central nervous system impairment, over traumatic spinal cord injury. Mild and moderate TBI cases represent more than 90% of TBI injuries but are unfortunately the most difficult to accurately diagnose. Currently, standard TBI diagnostic tools are based on CT scans, MRI scans or cognitive evaluations which are not always sufficient accurate to correctly diagnose mild and moderate cases, putting the patient at risks (long-term consequences of untreated TBI include headache, dizziness, irritability, anxiety and depression). Medicortex is an innovative point of care test based on novel glycan-based biomarkers. The Medicortex diagnostic kit is a cost-efficient, quick and reliable test based on specific biomarkers for the identification of TBI in both saliva and urine samples. We have protected the innovation with several patents. Many biomarkers have been suggested for TBI but none has resulted in an approved test. We have already proven that our biomarker is strongly correlated with TBI, allowing us to address a TBI point of care (POC) diagnostics market that will exceed €2 billion annually. We will sell the Medicortex TBI tests and envision a price to distributors of €25. We expect distributors to charge €50 to healthcare providers and make a margin of 50%. This will reduce the TBI diagnostics cost by a factor of 10-25x for healthcare systems as a single test can be charged to the patient for less than €100 instead of €1,000 for a CT scan or €2,500 for an MRI scan. Two distributors have confirmed they interest in a letter. Our Founder Dr. Harel has many years of experience in the pharmaceutical and biotech industry. Our Medical Director Dr. Mårten Kvist is active in academia and our Head of R&D Dr. Lasse Välimaa has a track record in R&D of bioanalytical methods and medical diagnostics.

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "MEDICORTEX" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "MEDICORTEX" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.3.;H2020-EU.2.3.;H2020-EU.2.1.)

ECOBIOMASS (2019)

Achieving unique wines through an efficient production process

Read More  

DetectInMen (2019)

Infection detection in human semen

Read More  

Dyme (2019)

Dyme gives its users complete control over their financial situation. The Dyme application provides insight into users’ spending and subscriptions, and lets users cancel, negotiate, or switch any cont

Read More